$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
吉瑞替尼开启FLT3突变型AML靶向治疗新时代
2025-10-19 11:44:20
Check Details
宜昌哪里可以买到吉瑞替尼呢?能用医保吗?
2025-10-19 11:44:20
Check Details
数据更新:Scemblix®治疗慢性髓系白血病患者,48周时仍在缓解!
2025-10-19 11:44:20
Check Details
阿扎胞苷片在美国获批维持治疗急性髓性白血病(AML)
2025-10-19 11:44:20
Check Details
缓解期AML患者首个一线口服维持疗法-阿扎胞苷片
2025-10-19 11:44:20
Check Details
治疗急性髓性白血病吉妥单抗新药介绍!
2025-10-19 11:44:20
Check Details
阿卡替尼VS伊布替尼:阿卡替尼治疗CLL的毒副作用更小,安全性更高
2025-10-19 11:44:20
Check Details
Magrolimab治疗急性髓细胞白血病的临床招募已经启动
2025-10-19 11:44:20
Check Details
抗癌药杜韦利西布可用于治疗三种淋巴瘤
2025-10-19 11:44:20
Check Details
尼洛替尼注意事项有哪些?尼洛替尼疗效怎么样?
2025-10-19 11:44:20
Check Details
美国PH+慢性粒细胞白血病的一线用药—博舒替尼
2025-10-19 11:44:20
Check Details
博舒替尼(Bosutinib)在国内上市了吗?多少钱一盒
2025-10-19 11:44:20
Check Details
1
2
...
647
648
649
650
651
652
653
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
2
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
3
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
4
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
5
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
6
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
7
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
8
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment